July 29, 2024 12:54 PM EDT
People
Cell/Gene Tx
Manufacturing

Pfiz­er cuts 210 North Car­oli­na work­ers af­ter it of­fi­cial­ly dis­con­tin­ues failed Duchenne gene ther­a­py

Kyle LaHucik

Senior Reporter

Pfiz­er will end de­vel­op­ment on its ex­per­i­men­tal Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py af­ter a Phase 3 fail­ure last month, and plans to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Sum­mit's Phase 3 da­ta back up biotech's boasts of beat­ing Keytru­da in lung can­cer

Ex­clu­sive: In­flu­en­tial De­mo­c­rat will op­pose Biose­cure Act ahead of House vote

Astel­las CEO talks fu­ture be­yond Xtan­di as Japan­ese drug­mak­er puts roots in Boston

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

sponsored

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

A service from the Financial Times